CN1253151C - mGluR5拮抗剂用于治疗瘙痒症的用途 - Google Patents

mGluR5拮抗剂用于治疗瘙痒症的用途 Download PDF

Info

Publication number
CN1253151C
CN1253151C CNB028046307A CN02804630A CN1253151C CN 1253151 C CN1253151 C CN 1253151C CN B028046307 A CNB028046307 A CN B028046307A CN 02804630 A CN02804630 A CN 02804630A CN 1253151 C CN1253151 C CN 1253151C
Authority
CN
China
Prior art keywords
alkyl
hydrogen
alkoxy
bis
carboxyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB028046307A
Other languages
English (en)
Chinese (zh)
Other versions
CN1535143A (zh
Inventor
F·加斯帕里尼
L·厄本
J·G·迈因加斯内
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of CN1535143A publication Critical patent/CN1535143A/zh
Application granted granted Critical
Publication of CN1253151C publication Critical patent/CN1253151C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
  • Steroid Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
CNB028046307A 2001-02-07 2002-02-06 mGluR5拮抗剂用于治疗瘙痒症的用途 Expired - Fee Related CN1253151C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0103045.1 2001-02-07
GBGB0103045.1A GB0103045D0 (en) 2001-02-07 2001-02-07 Organic Compounds

Publications (2)

Publication Number Publication Date
CN1535143A CN1535143A (zh) 2004-10-06
CN1253151C true CN1253151C (zh) 2006-04-26

Family

ID=9908300

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB028046307A Expired - Fee Related CN1253151C (zh) 2001-02-07 2002-02-06 mGluR5拮抗剂用于治疗瘙痒症的用途

Country Status (13)

Country Link
US (2) US20040106582A1 (enExample)
EP (1) EP1359905B1 (enExample)
JP (2) JP2004517947A (enExample)
CN (1) CN1253151C (enExample)
AT (1) ATE333869T1 (enExample)
AU (1) AU2002231777A1 (enExample)
BR (1) BR0206917A (enExample)
CA (1) CA2433409C (enExample)
DE (1) DE60213365T2 (enExample)
ES (1) ES2271229T3 (enExample)
GB (1) GB0103045D0 (enExample)
PT (1) PT1359905E (enExample)
WO (1) WO2002062323A2 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0128996D0 (en) 2001-12-04 2002-01-23 Novartis Ag Organic compounds
GB0322612D0 (en) * 2003-09-26 2003-10-29 Novartis Ag Organic compounds
EP1677790A1 (en) * 2003-10-31 2006-07-12 AstraZeneca AB Alkynes ii
EP1677789A1 (en) * 2003-10-31 2006-07-12 AstraZeneca AB Alkynes i
EP1677788A1 (en) * 2003-10-31 2006-07-12 AstraZeneca AB Alkynes iii
GB0503646D0 (en) * 2005-02-22 2005-03-30 Novartis Ag Organic compounds
GB0508319D0 (en) 2005-04-25 2005-06-01 Novartis Ag Organic compounds
CA2881638A1 (en) 2012-08-30 2014-03-06 Nippon Shinyaku Co., Ltd. Pyridine derivative and medicine
JP6603334B2 (ja) * 2015-06-03 2019-11-06 エフ．ホフマン−ラ ロシュ アーゲー エチニル誘導体

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5013744B1 (en) * 1989-12-29 1994-09-20 Allegran Inc Acetylenes disubstituted with a pyridinyl group and a substituted phenyl group having retinoid like activity
FR2719044B1 (fr) * 1994-04-26 1996-05-31 Cird Galderma Nouveaux composés bi-aromatiques acétylénés à groupement adamantyle, compositions pharmaceutiques et cosmétiques les contenant et utilisations.
US5498795A (en) * 1994-12-29 1996-03-12 Allergan, Inc. Acetylenes disubstituted with hydroxyaryl and aryl or heteroaryl groups having retinoid-like biological activity
US5534641A (en) * 1994-12-29 1996-07-09 Allergan Acetylenes disubstituted with 2-tetrahydropyranoxyaryl and aryl or heteroaryl groups having retinoid-like biological activity
TW544448B (en) * 1997-07-11 2003-08-01 Novartis Ag Pyridine derivatives
US6774138B2 (en) * 1999-08-31 2004-08-10 Merck & Co., Inc. Thiazolyl(pyridyl)ethyne compounds

Also Published As

Publication number Publication date
ATE333869T1 (de) 2006-08-15
DE60213365D1 (de) 2006-09-07
PT1359905E (pt) 2006-11-30
JP2004517947A (ja) 2004-06-17
CA2433409C (en) 2010-04-20
CN1535143A (zh) 2004-10-06
DE60213365T2 (de) 2007-08-09
WO2002062323A3 (en) 2003-03-20
BR0206917A (pt) 2004-02-03
US20040106582A1 (en) 2004-06-03
EP1359905B1 (en) 2006-07-26
CA2433409A1 (en) 2002-08-15
AU2002231777A1 (en) 2002-08-19
EP1359905A2 (en) 2003-11-12
ES2271229T3 (es) 2007-04-16
GB0103045D0 (en) 2001-03-21
JP2012131829A (ja) 2012-07-12
WO2002062323A2 (en) 2002-08-15
US20070265279A1 (en) 2007-11-15

Similar Documents

Publication Publication Date Title
CN1187048C (zh) mGLuR拮抗剂用于治疗疼痛和焦虑
JP2012131829A (ja) そう痒状態の処置のためのｍｇｌｕｒ５アンタゴニストの使用
KR101701943B1 (ko) 당뇨병의 치료 또는 예방약
ZA200102637B (en) MGluR5 antagonists for the treatment of pain and anxiety.
JP2006131545A (ja) 神経因性疼痛治療剤
RU2275906C2 (ru) Средство для лечения болезни паркинсона, включающее в качестве активного ингредиента соединение, улучшающее астроцитную функцию
JP2004506619A (ja) 性的機能障害用医薬
JP3598116B2 (ja) 遅発性ジスキネジアの治療用医薬組成物とその利用
CA2684174C (fr) Utilisation du 4-cyclopropylmethoxy-n-(3,5-dichloro-1-oxydo-pyridin-4-yl)-5-(methoxy)pyridine-2-carboxamide pour le traitement des desordres moteurs lies a la maladie de parkinson
KR19990036248A (ko) 마약성 진통제의 의존·내성 형성 억제제
WO2007081060A1 (ja) 神経因性疼痛治療剤
JP2765698B2 (ja) アリールアルキルアミド含有の神経変性疾患治療剤
CN1447809A (zh) 神经变性疾病的预防和治疗药物
AU2002328569B2 (en) Medicinal compositions containing angiotensin II receptor antagonist
CN1968693A (zh) 包含乙酰胆碱酯酶抑制剂与5－取代－3－∴二唑基－1,6－萘啶－2(1h)－酮衍生物组合的药物
JP5559696B2 (ja) 糖尿病性腎症の治療剤
EP1406627B1 (fr) Derives de pyridin-2-yl-methylamine pour le traitement de la dependance aux opioides
WO1997027175A1 (en) SUBSTITUTED ETHYL α,α - DIARYLMETHYL ETHER DERIVATIVES
CN1466587A (zh) 含有2-芳基-8-氧代二氢嘌呤衍生物作为活性成分的痴呆症治疗剂
JP2006306738A (ja) 神経因性疼痛治療剤
WO2007026928A1 (ja) 神経因性疼痛治療剤
JPH0827029A (ja) ５ｈｔ１ 作動薬の新規医薬用途
WO1998003201A1 (fr) Nouvelles compositions medicinales a usage therapeutique

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C56 Change in the name or address of the patentee

Owner name: NOVARTIS CO., LTD.

Free format text: FORMER NAME: NOVARTIS AG

CP01 Change in the name or title of a patent holder

Address after: Basel

Patentee after: Novartis Ag

Address before: Basel

Patentee before: Novartis AG

CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20060426

Termination date: 20150206

EXPY Termination of patent right or utility model